- Research article
- Open Access
- Open Peer Review
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity
BMC Cancer volume 16, Article number: 667 (2016)
Histone deacetylase inhibitors (HDACi) exert multiple cytotoxic actions on cancer cells. Currently, different synthetic HDACi are in clinical use or clinical trials; nevertheless, since both pro-invasive and anti-invasive activities have been described, there is some controversy about the effect of HDACi on melanoma cells.
Matrigel and Collagen invasion assays were performed to evaluate the effect of several HDACi (Butyrate, Trichostatin A, Valproic acid and Vorinostat) on two human melanoma cell line invasion (A375 and HT-144). The expression of N- and E-Cadherin and the activity of the RhoA GTPase were analyzed to elucidate the mechanisms involved in the HDACi activity.
HDACi showed a pro-invasive effect on melanoma cells in vitro. This effect was accompanied by an up-regulation of N-cadherin expression and an inhibition of RhoA activity. Moreover, the down-regulation of N-cadherin through blocking antibodies or siRNA abrogated the pro-invasive effect of the HDACi and, additionally, the inhibition of the Rho/ROCK pathway led to an increase of melanoma cell invasion similar to that observed with the HDACi treatments.
These results suggest a role of N-cadherin and RhoA in HDACi induced invasion and call into question the suitability of some HDACi as antitumor agents for melanoma patients.
Gene expression in eukaryotic cells is epigenetically regulated by the antagonistic activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Histone acetylation by HATs mediates the formation of accessible chromatin regions and promotes gene expression, whereas histone deacetylation catalyzed by HDACs leads to a repressive state due to chromatin compaction. Given the capital function of these enzymes, their activities are tightly regulated.
The role of HDACs in cancer progression was first demonstrated in acute promyelocytic leukemia  and is currently known in many other tumor types, including melanoma [2–5]. Therefore, HDACs have emerged as a target for anticancer therapies and many authors have focused their research on this issue. As a consequence, it has been demonstrated that several HDAC inhibitors (HDACi) induce growth arrest, differentiation and apoptosis in different cancer cell lines [6–8]. Several HDACi have been previously used in clinical trials with different tumor types, including melanoma . In a phase I/II clinical trial of Valproic acid in combination with Topoisomerase I inhibitor, Karenitecin, 47 % of patients had stable disease with median progression-free survival of 10.3 weeks versus 34 % with stable disease with median progression-free survival of 7.9 weeks shown in patients on a previous phase II study with Karenitecin as a single agent . In another phase I study with the HDACi MS-275 disease stabilization and partial remission were observed in patients with melanoma and other solid tumors . Phase I clinical trials of vorinostat in combination with other drugs have shown interesting results on melanoma patients, with a significant percentage of disease stabilization and tumor measurement reduction. Nevertheless, no responses were shown under RECIST criteria .
HDACi have also been associated with the epithelial-to-mesenchymal transition (EMT) [13, 14], a process that contributes to invasion and progression of cancer cells. This process is characterized by the acquisition of an elongated fibroblast-like morphology, inhibition of cell adhesion and an increase of cell motility as one of its main hallmarks [15, 16].
HDACi can be classified into several structural classes including, in order of decreasing potency, hydroxamic acids, cyclic peptides, benzamides and aliphatic acids. Sodium butyrate is a fatty acid synthesized by intestinal bacteria that inhibits the cell cycle through the activation of the p21Waf1/Clip1 gene . We have previously shown that butyrate induces the apoptosis of melanoma cells in a synergistic manner when combined with resveratrol . In spite of the clear pro-apoptotic effect of butyrate and other HDACi, its effect on the invasive capability of cancer cells is still controversial. Some authors point to butyrate as an inhibitor of invasion in cancer cells [18–20], whereas others have observed the opposite result [16, 21]. Therefore, in order to characterize the effect of HDACi on human melanoma cells, we have evaluated the invasiveness of two human melanoma cell lines (A375, derived from a primary tumor, and HT-144, obtained from a subcutaneous metastatic site) treated with a variety of HDACi, two of them were hydroxamic acids (Trichostatin A and Vorinostat) and the other two were aliphatic acids (Butyrate and Valproic acid). We have also analyzed the effect of these inhibitors on cadherin expression and RhoA activity. Our results demonstrate that most HDACi promote melanoma cell invasion in vitro after 24 h. Moreover, this pro-invasive response to HDACi could be mediated by the E- to N-cadherin switch at the cell-cell adhesion complexes and a decrease in the activity of RhoA small GTPase.
A375 and HT-144 melanoma cell lines were purchased from ATCC. Cells were grown in DMEM growth medium supplemented with 10 % Fetal Bovine Serum, 1 % L-Glutamine and 1 % Penicillin-Streptomycin. Cells were maintained at 37 °C in an incubator with a 5 % CO2 humidified atmosphere, and were subcultured every 2–3 days with trypsin-EDTA solution.
Melanoma cells were treated with 2 mM butyrate (Sigma-Aldrich, St. Louis, MO), 100 nM TSA (Sigma-Aldrich, St. Louis, MO), 1 mM valproic acid (Sigma-Aldrich, St. Louis, MO) and 3 μM vorinostat (Selleckchem, Houston, TX). In order to minimize the interference of apoptosis in the quantification of cell invasiveness we have used low concentrations of HDACi among the standard range found in the literature [6, 22–29]. The cells were exposed to the HDACi during 24 h in all the experiments except if something different is specified.
Drug sensitivity assay
A375 and HT144 cells were seeded at 10,000 cells/well and 5000 cells/well respectively in triplicate in 96-well plates and treated for 24 h with varying concentrations of Butyrate, TSA, Valproic acid and Vorinostat (Fig. 1). After 24 h, relative viable cell numbers were determined using the MTT viability Assay (Sigma), which measures bioreduction of MTT into a soluble formazan that was measured in a microplate reader at A540 nm.
Flow cytometric analysis of apoptosis
A375 melanoma cells were treated with HDAC inhibitors as indicated above during 24 and 48 h, cells were then harvested, washed and stained using the apoptosis detection kit Annexin V FITC of Immunostep (Salamanca, Spain) according to the manufacturer’s recommendations. Samples were acquired on a Gallios flow cytometer (Beckman Coulter, Brea, CA). Acquired samples were analyzed using Kaluza software (Beckman Coulter, Brea, CA).
Matrigel invasion assay
Matrigel is an extracellular matrix component similar to the basal membrane that separates epidermis and dermis so we decided to use this assay to evaluate the invasiveness of a primary tumor derived cells (A375). We used 6.5 mm diameter Transwell inserts (Costar) with 8 μm pore membranes. The membranes were coated with 35 μl Matrigel (BD Biosciences) at 3 mg/ml in serum-free DMEM and allowed to solidify in the incubator at 37 °C for 2 h. Cells were detached, washed twice with PBS and re-suspended in serum-free DMEM. 5×105 cells in 50 μl were placed in the upper chamber with the corresponding treatment, and the lower chamber was filled with 1 ml of DMEM-10 % FBS. After a 24 h incubation period, the cells that remained in the upper chamber were scraped away. Cells in the lower surface of the membrane were stained with Hoechst for 15 min. Pictures of the lower surface of the insert were taken with a confocal microscope (Olympus Fluoview FV500) using a 4× objective capturing the central area of the membrane (9 mm2). Invading cell number was quantified with the ImageJ software.
Collagen invasion assay
Type I collagen is the most abundant component of the connective tissue of the dermis so it was used to analyze the invasion of cells derived from a subcutaneous metastatic site (HT-144). The type I collagen solution was prepared mixing the following components at 4 °C: four volumes of type I collagen (3.49 mg/ml), five volumes of calcium-magnesium-free Hank’s balanced salt solution, one volume of MEM (10×), one volume of 0.25 M NaHCO3, 2.65 volumes of culture medium, and 0.3 volumes of 1 M NaOH. 1.25 ml of type I collagen solution was added to each well of six-well plates, homogeneously spread, and solidified for one hour at 37 °C on a flat surface in a humidified atmosphere with 5 % CO2. 105 single cells suspended in 1 ml of culture medium with the corresponding treatment were seeded on top of the type I collagen gel and maintained at 37 °C in an incubator.
Cell morphology was studied and invasion was scored after 24 h of incubation. The number of invasive and noninvasive cells was counted in ten randomly selected microscopic fields with a 20× objective using an inverted phase contrast microscope (Nikon Eclipse Ti-S). The invasion index was calculated as the ratio of the number of invading cells, which showed dark protrusions in their membrane, divided by the number of non-invasive cells counted in each field. Then, control was set as 100 and the other data relative to control. For the phalloidin staining collagen gels were fixed with 3 % paraformaldehyde, permeabilized with 0.5 % Triton, and then incubated with Phalloidin-TRITC and DAPI for 30 min. Actin cytoskeleton images were taken with a confocal microscope (Olympus Fluoview FV500).
Pictures of phalloidin stained HT-144 cells invading collagen after 24 h of culture (with or without HDACi) were taken with a confocal microscope (Olympus Fluoview FV500) at low magnification (10× objective). Then shape factor, or circularity factor, was measured with Image J as 4 πA/P2, with A being the area and P the perimeter of the cell. Shape factor is measured from 0 to 1. A shape factor of 1 corresponds to a round cell, as shape factor goes to zero cells are assumed to be increasingly more spread. Ten pictures of three independent experiments were evaluated for each condition.
Protein extraction and Western Blot
Cells were lysed in 1× Laemmli buffer and protein concentrations were determined via Bio-Rad Rc-Dc protein assay in accordance with the manufacturer’s instructions. Twenty-five nanogram of proteins were transferred to PVDF membranes. The membranes were probed with the corresponding antibodies, incubated with diluted HRP-linked secondary antibody and visualized by enhanced chemiluminescence (ECL) in accordance with the recommended procedure.
To study the function of cadherins we performed immunoprecipitation with α-catenin in order to precipitate proteins in the cadherin/catenin complex from cell extracts of untreated and HDACi treated (24 h) cultures. Immunoprecipitation for α-catenin was carried out with magnetic beads (Dynabeads M-280 Sheep anti- Rabbit IgG). Magnetic beads were incubated with α-catenin antibody for 2–4 h at 4 °C. After antibody incubation, cell lysates, made in NP40 lysis buffer (1 % NP40 PBSD+), were added and incubated overnight at 4 °C. Then beads were washed five times for 5 min and finally denatured in boiling Laemmli buffer (1 ml Laemmli 1.5×, 75 μl β-mercaptoethanol y 75 μl bromophenol blue). Finally, cadherins and catenins were detected by Western blot.
Rho pull down assay
GTP-bound Rho GTPase was pulled down with rhotekin RBD protein GST beads (Cytoskeleton Inc, Denver, CO) according to the manufacturer’s instructions from cell lysates of A375 cells untreated or treated for 48 h with HDACi. Cells were lysed in PIPES 50 mM at pH 7 (0.130 mM NaCl, 1 mM PMSF, 1 mM DTT, 5 μl/ml leupeptin and 0,5 % Triton X-100). Later, samples were diluted to 0.5 mg/ml in lysis buffer (50 mM Tris pH 7.5, 10 mM MgCl2, 0.3 M NaCl, 2 % IGEPAL) with a protease inhibitor cocktail. Samples were centrifuged at 14,000 rpm at 4 °C for 15 min and 1/10th volume of loading buffer was added (150 mM EDTA). GTPγS 0.2 mM and GDP 1 mM were added to two control lysates as positive and negative control respectively.
Samples were incubated 15 min at room temperature and reaction was stopped with stop buffer (600 mM MgCl2) to a final concentration of 60 mM. Then, protein beads were resuspended, 20 μl were added to each tube, and gently rotated at 4 °C for 1 h. Beads were washed twice with 500 μl of wash buffer (25 mM Tris pH 7.5, 30 mM MgCl2, 40 mM NaCl) and centrifuged at 5000 rpm for 1 min a 4 °C. Finally, beads were resuspended in SDS buffer and analyzed by Western Blot using a RhoA specific monoclonal antibody.
HT-144 cells were cotransfected with two vectors encoding RhoA dominant negative (RhoA-T19N) and the green fluorescent protein (GFP) at a 5:1 ratio. 48 h after transfection, the percentage of GFP expressing cells was analyzed by flow cytometry to evaluate transfection efficiency. Transfection was performed using Xfect (Clontech) following the manufacturer’s instructions. The collagen invasion assay was performed 48 h after transfection.
Antibodies against E-cadherin (HECD1) and RhoA were acquired from Takara and Upstate respectively. Antibodies for α-catenin and N-cadherin were purchased from Sigma. The neutralizing antibody against N-cadherin GC-4 was also acquired from Sigma.
2,5×105 HT-144 cells were plated in 6-well plates and 24 h later transfected with iRNAmax Lipofectamine and siRNAs targeting N-cadherin , purchased to Qiagen: Inhibition of N-cadherin expression was achieved by RNA interference using a 1:1 mixture of the following double-stranded oligoribonucleotides (1,5 μl each from 10 μM solution in 9 μl of Lipofectamine): siN-CAD2 5-AGUGGCAAGUGGCAGUAAA-3 and siN-CAD3 5-GGAGUCAGCAGAAGUUGAA-3’. To verify the specificity of the silencing effect we also used a sequence with no known mammalian target as a control (con 5-UUCUCCGAACGUGUCACGU-3). Forty-eight hours after transfection collagen invasion assays were performed in the same conditions as those used with no transfected cells. Cells lysates were obtained to confirm silencing.
Values in the figures are expressed as means ± S.D. Statistical analyses were conducted using the Student t-test for the comparison of two data groups with GraphPad (Prism4).
HDACi sensitivity assay
Cells were treated for 24 h with varying concentrations of Butyrate (1, 2, 4, 8 and 16 mM), TSA (50, 100, 200, 300 and 400 nM), Valproic acid (0.5, 1, 2, 4 and 8 mM) and Vorinostat (1.5, 3, 6, 12 and 24 μM). Viable cell numbers were determined by colorimetric assay, and plotted relative to untreated control cells (Fig. 1). At the concentrations selected for the invasion assays HDACi reduced the number of viable cells in both A375 (by 3–15 %) and HT-144 (by 13–25 %) melanoma cells. HT-144 cells were more sensitive to all HDACi than A375 cells (Fig. 1).
HDACi induce melanoma invasion in Matrigel and type I collagen
In order to elucidate the role of HDACi in the invasive ability of melanoma cells, we have tested the effect of four different HDACi on A375 and HT-144 melanoma cell lines using Matrigel and type I collagen invasion assays. Our results show that A375 cell invasion is significantly increased in Matrigel when treated with butyrate, TSA, valproic acid or vorinostat during 24 h (p < 0.001) (Fig. 2 a). In contrast, HT-144 cells treated with butyrate (p < 0.01), TSA (p < 0.001) and vorinostat (p < 0.001) show significantly higher invasion into type I collagen when compared to untreated cultures (Fig. 2 c). Nevertheless, HT-144 cell invasiveness does not undergo significant changes in response to valproic acid (Fig. 2 c).
HDACi induce apoptosis in melanoma cells
To analyze the induction of apoptosis by the HDACi at the selected concentrations we determined the number of Annexin V stained cells after 24 and 48 h of treatment. The number of cells undergoing apoptosis at 24 h in the untreated A375 culture was 11.7 %, this value was similar, or even lower, in the cultures treated with TSA (10.4 %) and valproic acid (7.4 %) but it was slightly increased with butyrate (17.2 %) and vorinostat (15.3 %). The effect of HDACi on apoptosis induction was higher after 48 h, the basal level of apoptotic cells observed in the untreated A375 cells (12.6 %) was significantly increased in the cultures treated with butyrate (18.1 %), valproic acid (20.4 %) and vorinostat (27 %). TSA (11 %) was the only inhibitor that did not show significant changes in the apoptosis levels after 48 h.
HDACi treatment leads to changes in HT-144 melanoma cell morphotype
After 24 h of treatment with any of the different HDACi, HT-144 cells exhibited a more elongated shape than their untreated counterparts (Fig. 3). In untreated cultures, HT-144 cells were mostly round-shaped and just about 20 % of the cells appear slightly elongated. However, the proportion of elongated cells increased up to 75 % after exposure to HDACi. We also observed that the intensity of the effect of each inhibitor on the morphology of melanoma cells was heterogeneous. Thus, butyrate and valproic acid induced subtle cell elongation at 24 h, while TSA and vorinostat had a dramatic effect on the morphotype, with the presence of long projections and mesenchymal-like cell appearance. Shape factor, which is around 0.8 in the control, decreased to almost 0.3 in the presence of some of the inhibitors. TSA and vorinostat had the strongest effect on shape factor with average values of 0.34 and 0.42 respectively, whereas butyrate (0.62) elicited a milder response. In contrast, valproic acid was the only inhibitor that did not induce a significant effect on shape factor. It should be taken into account that the percentage of elongated cells differed among the different treatments. Thus, it was around 40 % in butyrate or TSA treated cultures whereas it reached 80 % of total cells in response to vorinostat.
HDAC inhibitors increase N-cadherin expression in melanoma cells
The switch from E-cadherin to the mesenchymal cell associated N-cadherin has often been observed during cancer progression. Therefore, the expression of both E- and N-cadherin was analyzed by Western blot in HT-144 and A375 cell lines treated with HDACi. The expression of the two analyzed cadherins was significantly increased in both cell lines in response to 24 h treatments with butyrate and valproic acid, with a remarkable effect on HT-144 cells (Fig. 4). In contrast, TSA and vorinostat had a very slight or null effect on cadherin expression levels.
In order to analyze the functionality of E- and N-cadherin, we determined their association with α-catenin through immunoprecipitation (Fig. 5). Our results show that, even though the expression of total E-cadherin is up-regulated by butyrate and valproic acid, these inhibitors induce a switch from E-cadherin to N-cadherin in the association with the α-actin cytoskeleton through α-catenin. The increase of α-catenin-associated N-cadherin is especially relevant in melanoma cells treated with sodium butyrate.
The inhibition of N-cadherin abrogates HDACi induced invasion
To demonstrate the direct implication of N-cadherin in HDACi-induced invasion, we performed collagen invasion assays with melanoma cells treated with butyrate, TSA and vorinostat, while blocking N-cadherin with an anti-N-cadherin monoclonal antibody (GC-4 mAb) (Fig. 6 a). In these experiments, the pro-invasive effect of the HDACi was completely abrogated when the blocking antibody was added to the culture medium. Additionally, the silencing of N-cadherin using specific siRNA in HT-144 cells abrogates the butyrate-induced invasion in a similar way to that observed with blocking antibodies, which constitutes an additional evidence for N-cadherin to be a mediator of HDACi-induced invasion. Interestingly, neither the blocking antibodies nor the siRNA have any effect on melanoma cell basal invasion (Fig. 6 b). This result suggests that the basal invasion observed in untreated cells does not depend on N-cadherin and that the proinvasive effect of HDACi might be due to some signaling triggered by the disturbance of the cadherin balance in favor to N-cadherin.
RhoA downregulation induces HT-144 cell invasion
In order to evaluate the possible role of small GTPases in the pro-invasive activity of HDACi, we performed a pull down assay for active RhoA in cell lysates from A375 cells untreated or treated for 48 h with HDACi. Our results show that there is a significant downregulation of active RhoA when cells are treated with butyrate, TSA and vorinostat (Fig. 7a), whereas a slight inhibition is observed with valproic acid.
Subsequently, we analyzed the role of the Rho/ROCK pathway in the invasive ability of melanoma cells. To this end, we performed a collagen invasion assay adding the Rho and ROCK inhibitors C3T and Y-27632, respectively. Both inhibitors emulate the pro-invasive effect of HDACi (Fig. 7 b). The collagen invasion assays performed using HT-144 cells transfected with dominant-negative RhoA (T19N) yielded similar results, confirming that the down-regulation of RhoA mimics the effects of HDACi in HT-144 cells.
Alterations in cell–cell adhesion, cytoskeleton reorganization and the acquisition of mesenchymal cell morphology are processes frequently observed during embryonic development, wound healing and several diseases, including cancer [31, 32]. These modifications may promote carcinoma cells to acquire invasion ability, which constitutes a critical step in tumor malignancy and metastasis [33, 34]. The E- to N-cadherin switch has been related to increased cell invasion, tumor progression and metastasis in melanoma and other carcinomas [30, 35–37].
Rho GTPase, which plays an important role in the regulation of the actin cytoskeleton, has also been associated with cancer invasion [38, 39]. Nevertheless, its role in tumor progression is still not clear, since the increased cell invasiveness has been associated with both the activation and the inhibition of Rho [30, 40–42].
The acetylation/deacetylation of chromosomal histones, regulated by HDACs and HATs, is an important epigenetic mechanism involved in the regulation of gene expression . Currently, HDACi appear as promising antitumor drugs due to their ability to suppress proliferation and induce apoptosis [2, 44]. Nevertheless, there is some controversy about how HDACi affect the invasive potential of cancer cells. Some studies describe an anti-invasive activity of HDACi [2, 18–20, 44] whereas other authors affirm that these inhibitors increase invasion in several cancer cell lines [10, 21].
In the present study, we have demonstrated that several HDACi induce the up-regulation of N-cadherin and a significant inhibition of Rho activity in melanoma cell lines. Moreover, all these modifications lead to an increased invasiveness of melanoma cells into Matrigel and type I collagen matrices. Of the four HDACi examined, Butyrate, TSA and vorinostat are the most effective in inducing melanoma invasion; valproic acid show a pro-invasive activity on A375 but fail to induce invasion in HT-144. These results correlate with the modifications in the adhesion molecules and Rho activity observed in the HDACi treated cells. Butyrate, TSA and vorinostat significantly inhibit the activity of RhoA in melanoma cells, whereas valproic acid does not produce significant changes in this parameter. The distinct effects of Rho inhibition on cancer cell invasion has been related to the expression of its different isoforms  and the activity of the zinc-finger transcription factors Snai1 and Snail2 . Moreover, it has been demonstrated that the down-regulation of Rho GTPase activity is able to induce collective cell migration through the stimulation of filopodia formation , in line with our morphological observations of HDACi treated melanoma cells. In this study we have also shown that the inhibition of the Rho/ROCK pathway by specific inhibitors or dominant-negative RhoA transfection leads to the same pro-invasive effect obtained with HDACi. This result suggests a direct implication of this pathway in the melanoma response to HDACi treatments.
Butyrate, TSA, valproic acid and vorinostat increase the association of N-cadherin with α-catenin, and thus, with the actin cytoskeleton. Butyrate does not alter the levels of E-cadherin linked to α-catenin, but does lead to the highest upregulation of functional N-cadherin. The effect of TSA and valproic acid on N-cadherin is lower than the effect of butyrate. However, they produce a significant downregulation of the E-cadherin association to alpha catenin. Surprisingly, vorinostat increases the association of both E-cadherin and N-cadherin to alpha catenin. Nevertheless, the dominance of the N-cadherin derived phenotype when the two cadherins are present has been previously demonstrated . In the present study we demonstrate that the pro-invasive effect of butyrate, TSA and vorinostat on melanoma cells is completely abrogated through the inhibition of N-cadherin by a specific blocking antibody and siRNA. It is also noteworthy that several studies indicate that cadherin-mediated cell-cell adhesion and Rho small GTPase activity are reciprocally modulated [47, 48]. As we have previously mentioned, it is intriguing that the basal melanoma invasion observed in control cultures are not reduced by any of the methods used for N-cadherin inhibition. Our hypothesis is that this basal invasion is N-cadherin independent and that the increase in melanoma cell invasion in response to HDACi might be the result of some kind of signaling pathway triggered by the disturbance of the cadherin balance in favor to N-cadherin. Further research should be done in order to identify the mechanisms involved in this process. The identification of these mechanisms could help to understand the differences observed between Matrigel and collagen invasion assays, what could be related with the different composition of these ECM. Our results show that the proinvasive effect of HDACi is more effective on Matrigel than in collagen type I, what suggests that cell-matrix adhesion molecules with higher affinity for laminin or collagen type IV could be involved in the invasion process.
Taken all together, our results indicate that the heterogeneity of the melanoma cell response to the different HDACi, especially evident in HT-144 cells, is the result of a balance between the pro-apoptotic and pro-invasive effects of these drugs. We have found a reduction in the number of viable melanoma cells treated with HDACi which ranges from 3 to 25 %. This reduction is due to the combination of the well-known HDACi induced cell cycle arrest [17, 49] and the induction of apoptosis, which we have shown to be slightly increased after 24 h of exposure to the drugs. Accordingly, the failure of valproic acid to increase the number of invasive HT-144 cells in the collagen invasion assay could be partially explained by the significant reduction of viable HT-144 cell numbers produced by this drug, which also fails to inhibit the activity of RhoA. On the other hand, vorinostat had a antiproliferative effect which was similar to that of valproic acid on HT-144 cells but, at the same time, it produced the highest pro-invasive response in these cells. This apparently contradictory result could be explained by its very effective inhibition of the RhoA GTPase activity. Thus, the effect of HDACi on melanoma cell invasion is likely the result of a combination of several modifications in cell homeostasis in addition to apopotisis, N-cadherin induction or RhoA inhibition. Further research would be useful to clarify this issue.
HDACi are currently in use in clinical trials against several cancer types . Our results have demonstrated that HDACi induce melanoma cell invasion in vitro. According to the present study, the use of HDACi in melanoma patients could facilitate metastasis through the up-regulation of N-cadherin and the inhibition of RhoA activity. This finding sheds light on our understanding of the role of HDACi in tumor progression, but it also warrants caution regarding the use of these agents in the treatment of melanoma. Further investigations into the effects of HDACi should be carried out to elucidate the molecular mechanisms underlying their pro-invasive effects on melanoma cells. These investigations may provide the necessary insight to neutralize the potentially adverse effects of HDACi.
Epithelial to mesenchymal transition
Green fluorescent protein
Histone acetyl transferase
Histone deacetylase inhibitor
Lin RJ, Nagy L, Inoue S, Shao W, Miller Jr WH, Evans RM. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature. 1998;391:811–4.
Chen S, Zhao Y, Gou WF, Zhao S, Takano Y, Zheng HC. The Anti-Tumor Effects and Molecular Mechanisms of Suberoylanilide Hydroxamic Acid (SAHA) on the Aggressive Phenotypes of Ovarian Carcinoma Cells. PLoS ONE. 2013;8:e79781.
Howell Jr PM, Liu S, Ren S, Behlen C, Fodstad O, Riker AI. Epigenetics in human melanoma. Cancer Control. 2009;16:200–18.
Petta V, Gkiozos I, Strimpakos A, Syrigos K. Histones and lung cancer: Are the histone deacetylases a promising therapeutic target? Cancer Chemother Pharmacol. 2013;72:935–52.
Yokoyama S, Feige E, Poling LL, Levy C, Widlund HR, Khaled M, Kung AL, Fisher DE. Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res. 2008;21:457–63.
Andrade R, Crisol L, Prado R, Boyano MD, Arluzea J, Aréchaga J. Plasma membrane and nuclear envelope integrity during the blebbing stage of apoptosis: a time-lapse study. Biol Cell. 2010;102:25–35.
Li ZH, Zhang XB, Han XQ, Feng CR, Wang FS, Wang PG, Shen J, Shi YK. Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer. Oncol Rep. 2013;30:499–505.
Salvador MA, Wicinski J, Cabaud O, Toiron Y, Finetti P, Josselin E, Lelièvre H, Kraus-Berthier L, Depil S, Bertucci F, Collette Y, Birnbaum D, Charafe-Jauffret E, Ginestier C. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. Clin Cancer Res. 2013;19:6520–31.
Nebbioso A, Carafa V, Benedetti R, Altucci L. Trials with ‘epigenetic’ drugs: an update. Mol Oncol. 2012;6:657–82.
Daud AI, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer 3rd FA, Lush R, Neuger A, Sullivan DM, Munster PN. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009;15:2479–87.
Gore L, Rothenberg ML, O’Bryant CL, Schultz MK, Sandler AB, Coffin D, McCoy C, Schott A, Scholz C, Eckhardt SG. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008;14:4517–25.
Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, Longenecker A, Lee L, Lay A, Sharma G, Gemmill RM, Drabkin HA, Lloyd GK, Neuteboom ST, McConkey DJ, Palladino MA, Spear MA. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. 2012;30:2303–17.
Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heidecke CD, Friess H, Büchler M, Evert M, Lerch MM, Weiss FU. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut. 2012;61:439–48.
Jiang GM, Wang HS, Zhang F, Zhang KS, Liu ZC, Fang R, Wang H, Cai SH, Du J. Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Biochim Biophys Acta. 1833;2013:663–71.
Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68:3033–46.
Tsai JH, Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013;27:2192–206.
Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr. 2003;133:2485–93.
Catalano MG, Fortunati N, Pugliese M, Marano F, Ortoleva L, Poli R, Asioli S, Bandino A, Palestini N, Grange C, Bussolati B, Boccuzzi G. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J Clin Endocrinol Metab. 2012;97:E1150–9.
Kuwajima A, Iwashita J, Murata J, Abe T. The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel. Anticancer Res. 2007;27:4163–9.
Wang F, Qi Y, Li X, He W, Fan QX, Zong H. HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9. Clin Invest Med. 2013;36:E87–94.
Pulukuri SM, Gorantla B, Rao JS. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J Biol Chem. 2007;282:35594–603.
Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res. 2005;11:4912–22.
Demary K, Wong L, Spanjaard RA. Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells. Cancer Lett. 2001;163:103–7.
Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P, La Porta CA. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis. 2004;9:573–82.
Chang J, Varghese DS, Gillam MC, Peyton M, Modi B, Schiltz RL, Girard L, Martinez ED. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br J Cancer. 2012;106:116–25.
Chodurek E, Orchel A, Gawlik N, Kulczycka A, Gruchlik A, Dzierzewicz Z. Proliferation and cellular death of A375 cell line in the presence of HDACs inhibitors. Acta Pol Pharm. 2010;67:686–9.
Gowda R, Madhunapantula SV, Desai D, Amin S, Robertson GP. Selenium-containing histone deacetylase inhibitors for melanoma management. Cancer Biol Ther. 2012;13:756–65.
Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD, Albelda SM. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009;8:2221–31.
Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja P, Seto E, Weber J, Sotomayor EM, Villagra A. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 2013;23:341–8.
De Wever O, Westbroek W, Verloes A, Bloemen N, Bracke M, Gespach C, Bruyneel E, Mareel M. Critical role of N-cadherin in myofibroblast invasion and migration in vitro stimulated by colon-cancer-cell-derived TGF-beta or wounding. J Cell Sci. 2004;15:4691–703.
De Wever O, Pauwels P, De Craene B, Sabbah M, Emami S, Redeuilh G, Gespach C, Bracke M, Berx G. Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front. Histochem Cell Biol. 2008;130:481–94.
Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15–33.
Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 2012;24:277–83.
Friedl P, Locker J, Sahai E, Segall JE. Classifying collective cancer cell invasion. Nat Cell Biol. 2012;14:777–83.
Rogers CD, Saxena A, Bronner ME. Sip1 mediates an E-cadherin-to-N-cadherin switch during cranial neural crest EMT. J Cell Biol. 2013;203:835–47.
Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res. 2005;18:150–9.
Lade-Keller J, Riber-Hansen R, Guldberg P, Schmidt H, Hamilton-Dutoit SJ, Steiniche T. E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression. Br J Dermatol. 2013;169:618–28.
Fortin Ensign SP, Mathews IT, Symons MH, Berens ME, Tran NL. Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression. Front Oncol. 2013;3:241.
Price LS, Collard JG. Regulation of the cytoskeleton by Rho-family GTPases: implications for tumour cell invasion. Semin Cancer Biol. 2001;11:167–73.
Bartolomé RA, Gálvez BG, Longo N, Baleux F, Van Muijen GN, Sánchez-Mateos P, Arroyo AG, Teixidó J. Stromal cell-derived factor-1alpha promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res. 2004;64:2534–43.
Shields MA, Krantz SB, Bentrem DJ, Dangi-Garimella S, Munshi HG. Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins. J Biol Chem. 2012;287:6218–29.
Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006;9:261–72.
Khan AN, Tomasi TB. Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res. 2008;40:164–78.
Cheng DD, Yang QC, Zhang ZC, Yang CX, Liu YW. Antitumor activity of histone deacetylase inhibitor TSA in osteosarcoma cells. Asian Pac J Cancer Prev. 2012;13:1395–99.
Ridley AJ. RhoA, RhoB and RhoC have different roles in cancer cell migration. J Microsc. 2013;251:242–9.
Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol. 1999;147:631–44.
Charrasse S, Comunale F, Grumbach Y, Poulat F, Blangy A, Gauthier-Rouvière C. RhoA GTPase regulates M-cadherin activity and myoblast fusion. Mol Biol Cell. 2006;17:749–59.
Laplante I, Béliveau R, Paquin J. RhoA/ROCK and Cdc42 regulate cell-cell contact and N-cadherin protein level during neurodetermination of P19 embryonal stem cells. J Neurobiol. 2004;60:289–307.
Wu Y, Guo SW. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol. 2008;137:198–203.
Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104:1828–35.
The authors would like to acknowledge the technical and human support provided by SGIker of UPV/EHU and European funding (ERDF and ESF). The authors also thank Dr. D. Fogarty and Mr. J. L. Vidaurrazaga for their critical reading and editorial assistance.
Research grants from the Spanish Ministry of Economy and Competitiveness (SAF2012-39773), the regional Basque Government Research Groups Program (T560-10) and the SAIOTEK Program of the Basque Science, Technology & Innovation net (SPRI) to J. Aréchaga supported this work. M. Díaz-Núñez held a fellowship from the University of the Basque Country and, later on, from the Jesús Gangoiti Barrera Foundation of Bilbao.
Availability of data and materials
The datasets analyzed during the current study are available from the corresponding author on reasonable request.
MD and AD performed the experiments and analysis and drafted this manuscript. AD and OW designed the research and drafted this manuscript. RA performed analysis of experiments and gave technical assistance with microscopes. JA (Arluzea) and MS helped to design the research and carried out critical revision of the manuscript. JA (Aréchaga) supervised experiments, revised the manuscript and obtained funding. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
About this article
Cite this article
Díaz-Núñez, M., Díez-Torre, A., De Wever, O. et al. Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity. BMC Cancer 16, 667 (2016) doi:10.1186/s12885-016-2693-3
- Histone deacetylase inhibitors
- Cell invasion